Human nanomedicine drug showing promise in solid cancers

January 9, 2018, The Ohio State University
Credit: The Ohio State University

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) is one of four cancer centers involved in testing a new "nanomedicine" agent – known as BXQ-350 while in testing – in advanced solid tumors, including difficult-to-treat malignant brain tumors.

BXQ-350 combines a protein called Saposin C, which is naturally expressed in humans, with nanobubbles of a fat molecule called DOPS. This combination creates a treatment agent that has the ability to selectively target cancerous cells and then kill them, largely sparing the surrounding healthy tissues. These fat nanoparticles can also penetrate the , which researchers say makes them particularly useful against malignant brain tumors.

"BXQ-350 is the first agent in this class of drugs and has unique properties not seen in conventional treatments. It is made of natural substances present in humans. Lab experiments have shown the agent has the ability to target cancer cells specifically and eliminate them," says Vinay Puduvalli, MD, director of neuro-oncology at the OSUCCC – James. "I believe that this research can potentially open new doors to the treatment of malignant tumors and other advanced cancers"

Recently reported clinical results from the phase I dose-escalation study show that the agent is well tolerated by patients; no dose-limiting toxicities have been observed, and no serious adverse events have been attributed to the therapy. The trial is accruing additional patients through an expanded phase IB trial, which is expected to enroll about 40 patients nationwide.

Patients with and advanced solid cancerous tumors who have not responded to other therapies may qualify for this therapy. BXQ-350 is available as part of a clinical trial underway only at the OSUCCC – James, University of New Mexico Cancer Center, University of Cincinnati Barrett Center and University of Kentucky Markey Cancer Center.

To learn more about clinical trials at the OSUCCC – James, visit cancer.osu.edu/clinicaltrials or call 1-800-293-5066.

Explore further: Onalespib could be an effective treatment for glioblastoma, preclinical studies show

Related Stories

Onalespib could be an effective treatment for glioblastoma, preclinical studies show

November 2, 2017
The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove ...

CAR-T immunotherapy now approved for certain adult lymphoma patients

October 20, 2017
The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced lymphoma. The therapy uses a patient's own white blood cells, which are modified in a lab and re-trained ...

Second generation BTK inhibitor highly effective as solo therapy in adult leukemia

December 13, 2017
Updated data on the first 134 chronic lymphocytic leukemia patients treated with single-agent acalabrutinib shows that the drug was well-tolerated in the majority of patients treated and responses were durable over time, ...

Nano drug crosses blood-brain tumor barrier, targets brain tumor cells and blood vessels

July 17, 2013
(Phys.org) —An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a recent study led ...

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Targeted therapies show initial effectiveness in subset of papillary thyroid cancer

June 5, 2017
Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer.

Recommended for you

Study may explain why some triple-negative breast cancers are resistant to chemotherapy

April 19, 2018
Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Protein can slow intestinal tumor growth

April 19, 2018
A new mechanism for regulating stem cells in the intestine of fruit flies has been discovered by researchers at Stockholm University. In addition, it was discovered that a certain protein can slow the growth of tumours in ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

An artificial mole as an early warning system

April 18, 2018
Alongside cardiovascular disease, cancer has become the top cause of death in industrialised countries. Many of those affected are diagnosed only after the tumour has developed extensively. This often reduces the chance of ...

Delivering cancer treatment on a nanodisc helps eliminate tumors

April 18, 2018
In the wrestling match with cancer, chemoimmunotherapy is the new strong arm, and it is building muscle with a nanodisc disguised as "good cholesterol."

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.